Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer

This study has been terminated.
(Incyte has suspended development of the compound.)
Sponsor:
Information provided by (Responsible Party):
Incyte Corporation
ClinicalTrials.gov Identifier:
NCT01254136
First received: December 1, 2010
Last updated: January 20, 2012
Last verified: January 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2011
  Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: December 13, 2010